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We have designed a novel, precise, and sensitive assay to measure unspliced (US) human immunodeﬁciency
virus type 1 (HIV-1) mRNA in peripheral blood mononuclear cells of HIV-1-infected individuals by using
real-time PCR and molecular beacons. Individuals were classiﬁed as either well suppressed (WS) or partially
suppressed, based on longitudinal measurements of plasma HIV-1 RNA. The proportion of individuals with US
mRNA undetectable over time was signiﬁcantly higher among WS individuals; however, 30% of WS subjects
still had detectable US mRNA after 24 months of effective antiviral therapy.
Effective antiviral therapy can suppress human immunode-
ﬁciency virus type 1 (HIV-1) replication to the extent that the
level of plasma viremia falls below a detectable level for over 2
years (10, 11, 19). However, the quantitative deﬁnition of “un-
detectable” is limited by the sensitivity of currently available
assays. Despite undetectable levels of HIV-1 RNA in plasma,
replication-competent virus can reside latently within resting
memory CD4
1 T lymphocytes (4). This reservoir persists even
after 2 years of seemingly effective antiviral therapy (5, 7, 30).
If replication of HIV-1 is effectively inhibited, the reservoir of
HIV-1 in resting memory CD4
1 T lymphocytes should decay
over time, with a half-life of ;6 months (13). However, if there
is persistent replication below the limits of detection of cur-
rently available assays, the reservoir will appear to persist
longer due to ongoing replenishment.
Studies of untreated HIV-1-infected individuals demon-
strate high levels of unspliced (US) and multiply spliced (MS)
mRNA in peripheral blood mononuclear cells (PBMC) in
roughly equimolar ratios (22–24, 28, 29). The overall amount
of HIV-1 mRNA expression strongly correlates with disease
progression (22–24, 29). Others report an association between
a reduced MS-to-US mRNA ratio and a poor prognosis (8, 17).
However, following treatment with effective antiviral therapy,
there is a rapid decrease of MS mRNA compared to US
mRNA in the ﬁrst 48 h (28), with most individuals having
undetectable MS mRNA by 2 weeks (1). Using a novel, rapid,
and accurate real-time PCR assay, we therefore undertook a
study to determine if the detection of US mRNA in PBMC of
individuals on effective antiviral therapy for at least 2 years
may serve as an indicator of persistent viral replication.
Total cellular RNA was extracted and reverse transcribed as
previously described (28). To detect the input copy number of
HIV-1 mRNA particles, a molecular beacon was used in com-
bination with real-time PCR. The method of detection using
molecular beacons (16, 27) and a ﬂuorescence detector system
(6, 9, 12, 26) has been previously described. Each 50-ml reac-
tion mixture contained 2 ml of cDNA from the reverse tran-
scription reaction, and the ﬁnal concentration of each compo-
nent was as follows: 1.03 Taqman buffer A (Perkin-Elmer,
Norwalk, Conn.), 3.5 mM MgCl2, 0.4 pmol of molecular bea-
con per ml, 0.4 pmol of each primer per ml, and 1.25 U of
AmpliTaq Gold DNA polymerase (Perkin-Elmer). The prim-
ers used have been previously described (28). The molecular
beacon was designed to recognize a conserved region within
the HIV-1 long terminal repeat (59-FAM-CGGGAGTACT
CACCAGTCGCCGCCCCTCGCCCTCCCG-DABCYL-39),
where 6-carboxyﬂuorescein (FAM) serves as the reporter
ﬂuorochrome and 4-dimethylaminophenylazobenzoic acid
(DABCYL) serves as the quencher (Fig. 1A). One cycle of
denaturation (95°C for 10 min) was performed, followed by 45
cycles of ampliﬁcation (95°C for 15 s, 55°C for 30 s, and 72°C
for 30 s). PCR was carried out in a spectroﬂuorometric thermal
cycler (ABI PRISM 7700; Applied Biosystems Inc.) that mon-
itors changes in the ﬂuorescence spectrum of each reaction
tube during the annealing phase while simultaneously carrying
out programmed temperature cycles.
For each run, a standard curve was generated from duplicate
samples of puriﬁed in vitro-transcribed US mRNA transcripts
(22) ranging from 50,000 to 10 copies (Fig. 1B and 1C). Each
test specimen was reverse transcribed and ampliﬁed in dupli-
cate. A third reaction mixture was processed and ampliﬁed,
without the addition of reverse transcriptase, to control for
potential DNA contamination. A sample was considered pos-
itive only if both replicates detected US mRNA. If one repli-
cate was negative and the other positive, it was assumed that
the concentration of US mRNA was at the lower limits of the
assay and the result was reported as ,50 copies/mg of RNA. Copy
numbers were calculated by interpolation of the experimen-
tally determined threshold cycle (CT) as previously described
(6, 9, 12, 26). To control for the recovery of intact PBMC RNA
and for the uniform efﬁciency of each reverse transcription
reaction, a 189-bp glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) fragment was ampliﬁed with speciﬁc primers (28).
GAPDH was quantiﬁed by using real-time PCR and a molec-
ular beacon (59-HEX-GCGTCGGCTCTCCAGAACATCAT
CCCTGCCTCGACGC-DABCYL-39), where hexachloroﬂuo-
rescein (HEX) served as the reporter ﬂuorochrome. The PCR
conditions were similar to those used for HIV-1 quantiﬁcation,
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6099except that the hybridization temperature was 60°C. A stan-
dard curve was generated with 10-fold dilutions of total RNA
quantiﬁed by spectrophotometry. The ﬁnal results were ex-
pressed as the mean copy number of US mRNA per micro-
gram of total RNA. For some individuals, MS mRNA was
ampliﬁed by nested conventional PCR as previously described
(28). The lower limit of sensitivity of this assay was 64 cop-
ies/mg of total RNA. All primer and beacon locations are
shown in Fig. 1A.
HIV-1-infected individuals were enrolled in treatment pro-
tocols within the ﬁrst 90 days after symptoms of primary HIV-1
infection. All individuals were receiving at least three antiret-
roviral drugs, including zidovudine (600 mg/day) and lamivu-
dine (300 mg/day), with either ritonavir (1,200 mg/day), indi-
navir (2,400 mg/day), or ritonavir (800 or 1,200 mg/day) with
saquinavir (800 or 1,200 mg/day). Individuals were classiﬁed as
either well suppressed (WS) or partially suppressed (PS) in
terms of viral load. With the Roche Ultrasensitive Amplicor
HIV-1 Monitor assay (lower limit of detection, 50 HIV-1 RNA
copies/ml; Roche Molecular Systems, Branchburg, N.J.) uti-
lized to measure plasma viremia monthly or bimonthly, WS
was deﬁned as #1 episode of detectable virus over the duration
of follow-up; PS was deﬁned as .1 episode of detectable virus
within the range of 50 to 400 copies per ml during the same
period.
In order to quantify residual viral replication in individuals
with sustained viral suppression, we compared WS and PS
individuals. The characteristics of the 27 male individuals (WS,
n 5 20; PS, n 5 7) are summarized in Table 1. All individuals
studied had undetectable virus, as measured by the Roche
FIG. 1. (A) Location of primers and beacon on the HIV-1 genome (adapted
from reference 22). The primers and beacon shown correspond to the following
positions on pNL4-3: H13, nucleotides (nt) 626 to 648; H4, nt 879 to 901; SL30,
nt 641 to 865; H10, nt 6070 to 6093; H2, nt 8504 to 8526; and H1, nt 6080 to 6102.
(B) Real-time PCR quantiﬁcation of HIV-1 US mRNA. A reading of change in
ﬂuorescence (Rn) as a function of cycle number is demonstrated for a range of
known input copy numbers of in vitro-generated HIV-1 US mRNA transcripts.
The copy numbers range from 50,000 to 50 copy equivalents per reaction. The
cycle number at which the mean ﬂuorescence rises 10 standard deviations above
the baseline is called the threshold cycle (CT). The CT is shown for duplicates of
the standards used. (C) Relationship of known number of HIV-1 transcripts to
the CT. The CT is directly proportional to the log of the input copy equivalents,
as demonstrated by the standard curve generated.
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20 months. The mean baseline plasma HIV-1 RNA level was
596,000 copies/ml and the mean baseline CD4 cell count was
500 cells/ml, with no signiﬁcant difference between WS and PS
individuals for either parameter. The median time it took to
achieve a plasma HIV-1 RNA level of ,400 to 500 copies per
ml was 45 days, with the median times for WS and PS groups
being 20 and 63 days, respectively (P 5 0.06, Mann-Whitney
rank sum test).
PBMC from these individuals were examined for the pres-
ence of US mRNA by using a novel real-time PCR assay
together with molecular beacons. The threshold sensitivity was
consistently 10 copy equivalents per reaction. The linear dy-
namic range is in excess of 5 log units (Fig. 1C). The linear
relationship between CT and the log of the input copy number
has been previously described (9, 12). Brieﬂy, the CT is the
cycle number at which the ﬂuorescence rises 10 standard de-
viations above the baseline. The CT values decrease linearly as
target quantity increases (Fig. 1C). The CT of duplicate sam-
ples of US RNA standards from eight experiments demon-
strated a mean coefﬁcient of variation of 1.4% (Fig. 1B). The
CT of duplicate aliquots of eight samples of PBMC mRNA
from infected individuals demonstrated a mean coefﬁcient of
variation of 0.65% (Fig. 1B). Based on studies of extraction
and analysis of four replicate aliquots of the same PBMC
samples from four individuals, the interassay variability of US
mRNA measurements averaged 28%.
In this study, PBMC US mRNA levels were assessed before
therapy and again at 12 and 24 months following the introduc-
tion of therapy. At each time point posttherapy the plasma
viral load was ,50 copies/ml. The results are summarized in
Fig. 2. Levels of US mRNA in PBMC declined on treatment
(median copy numbers [ranges] at 0, 12, and 24 months, re-
spectively, were as follows: 3,446 [84 to 24,333], 60 [,50 to
1,621], and ,50 [,50 to 720] for WS individuals and 3,487
[1,119 to 10,695], 193 [169 to 989], and 200 [,50 to 888] for PS
individuals; P 5 0.4, 0.03, and 0.11 [Mann-Whitney rank sum
test]). Individuals who had persistently detectable virus in the
periphery (n 5 3) always had detectable US mRNA (Fig. 2).
For some individuals, PBMC mRNA was assessed every 6
months. Longitudinal levels of CD4
1 T cells, plasma HIV-1
RNA, and US mRNA over time in representative subjects are
shown in Fig. 3. In all cases studied, US mRNA levels declined
within the ﬁrst 6 months of therapy. For most WS patients (14
of 20), US mRNA was undetectable after 24 months of ther-
apy. However, for some patients from whom samples were
taken more frequently, US mRNA was intermittently detect-
able (Fig. 3, patient 2002). For patients with partial suppres-
sion of plasma virus, US mRNA levels also declined initially,
though afterward, US mRNA was persistently detectable (Fig.
3, patient 2003).
We then assessed the proportion of individuals who had
persistently undetectable levels of US mRNA during the fol-
low-up period. The proportion of individuals with US mRNA
undetectable over time in a Kaplan-Meir analysis (at 0, 6, 12,
18, and 24 months) was signiﬁcantly higher among WS indi-
viduals (0, 0.2, 0.3, 0.6, and 0.7 for WS patients and 0, 0, 0, 0,
and 0.2 for PS patients). However, 6 of 20 WS individuals had
persistently detectable US mRNA after 24 months of unde-
tectable plasma viremia. In order to determine the signiﬁcance
of detectable US mRNA, PBMC from 14 of 20 WS individuals
and 2 of 7 PS individuals were assessed for the presence of MS
mRNA after 12 to 24 months of therapy. No individuals had
detectable MS mRNA.
The persistence of US mRNA in nearly all PS individuals
FIG. 2. Cross-sectional analysis of US mRNA copies per microgram of
mRNA in WS and PS individuals. Levels of US mRNA in PBMC from WS and
PS individuals (circles) and median values (black lines) are shown. Data from
three nonsuppressed individuals (diamonds) are shown as positive controls.
There is a signiﬁcant difference between WS and PS individuals in the levels of
US mRNA at 12 months (P 5 0.03) and 24 months (P 5 0.11). The lower limit
of detection of US mRNA was 50 copies/mg of total RNA.
TABLE 1. Characteristics of individuals studied
Characteristic Total WS PS
No. of subjects 27 20 7
No. of subjects on the
following drug
combination
a (mean
duration of follow-up):
AZT-3TC-IDV (34 mo) 10 8 2
AZT-3TC-RIT (28 mo) 5 3 2
AZT-3TC-SQV/RIT (22 mo) 12 9 3
Age (yr)
Mean 6 SD 33.3 6 7.0 32.6 6 6.5 35.2 6 7.0
Range 24.2–53.9 26.7–53.9 24.2–51.2
Baseline CD4 cell count/ml
Mean 500 517 433
Range 47–1,224 197–1,224 47–838
Baseline viral load
b,c
Mean 596 441 610
Range ,0.5–4,760 ,0.5–4,760 14.8–2,730
Time until viral load
b was
,400 (days)
Median 45 20 63
Range 0–182 0–182 33–132
Duration of viral load
d at
,50 (mo)
Median 20 20 19
Range 6–34 9–34 6–25
No. of episodes of viral load
d
at 50–400
Mean ,13
Range 0–1 2–5
a AZT, zidovudine; 3TC, lamivudine; RIT, ritonavir; SQV, saquinavir; and
IDV, indinavir.
b Viral load (branched DNA, copies per milliliter).
c Values are in thousands.
d Viral load (RT-PCR, copies per milliliter).
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plasma is biologically signiﬁcant and most likely represents
ongoing replication at the very lower limits of the sensitivity of
the assay. We do not know the duration of these intermittent
low-level rises in plasma virus, since for all PS individuals,
plasma RNA was undetectable 1 month later. However, in
contrast to the low-level ﬂuctuation of plasma viremia, US
mRNA remained persistently detectable for most of these in-
dividuals and may serve as a more sensitive indicator of ongo-
ing viral replication.
Within the WS group, 30% of individuals had persistently
detectable US mRNA. There are several possible explanations
for this observation. Firstly, the deﬁnition of WS is dependent
on sampling. Although in nearly all cases sampling was per-
formed monthly or bimonthly, if low-level intermittent viremia
was short-lived, then individuals could conceivably have been
incorrectly classiﬁed as WS. Secondly, even in truly WS indi-
viduals, residual viral replication may occur at a level below the
sensitivity of current plasma assays.
Studies of US and MS mRNA expression in cells infected in
vitro (14, 15, 21) and in activated latently infected cells (1, 18,
20) demonstrate an early rise in MS mRNA levels followed
within 5 to 24 h by a rapid rise in US mRNA levels. These
ﬁndings suggest that levels of MS mRNA in PBMC are closely
associated with the number of newly infected cells (1, 28).
Following treatment, there is a rapid decline in MS mRNA
levels within 48 h, but US mRNA persists (1, 28). Thus, the
absence of MS mRNA in most WS individuals, even in the
presence of US mRNA, is in agreement with these previous
reports.
Given the absence of MS mRNA, what are the possible
explanations for the persistence of US mRNA? The most likely
explanation is that ongoing replication could continue within a
site where antiviral therapy is ineffective. When cells from this
“privileged” site enter the bloodstream, contact with effective
antiviral drugs causes a rapid decline in the level of MS mRNA
but a slower decline in the level of US mRNA, and therefore
we are able to detect only persistently replenished reservoirs of
US mRNA. Ineffective antiviral therapy could also result in the
appearance of drug resistance. However, replication of resis-
tant virus would be unlikely, as studies of similar patients on
prolonged antiviral therapy with durable viral suppression do
not demonstrate emergence of drug resistance in virus isolated
from resting CD4
1 T cells (7, 30). Virus isolated from resting
CD4
1 T cells would be representative of both reservoirs of
infection, i.e., ongoing low-level productive infection as well as
the so-called “latent reservoir.” In future studies, we plan to
directly compare the quantity of virus isolated from this reser-
voir and the amount of detectable US mRNA. Alternatively,
there may be ongoing replication of infected cells, such as T
cells or macrophages, but with a very low level of viral expres-
sion. Another possibility is that the US mRNA represents
preintegration complexes between the entry and integration
stages in the viral life cycle (2, 3, 25, 31), but this is unlikely
given the predicted short half-life of this form of HIV-1 RNA
(2, 4). Finally, US RNA could represent viral RNA contained
in particles bound to the surfaces of unfractionated PBMC.
Our assay would be unable to differentiate between viral RNA
and mRNA. However, in our studies of lymphoid tissue of
patients with detectable US mRNA and undetectable MS
mRNA, in situ hybridization with radiolabeled RNA probes
revealed evidence of intracellular viral RNA, making bound
particles an unlikely explanation for the persistence of US
mRNA (data not shown).
The ability to quantify residual replication in individuals
with undetectable viremia is critical to determining future
management strategies for infected individuals. Current esti-
mates of the half-life of the latent reservoir suggest that 7 to 10
years of continuous truly effective therapy will be necessary to
eliminate the latent reservoir (13). However, if therapeutic
FIG. 3. Sequential changes in plasma viral load (squares in top row), CD4 lymphocyte count (circles), and US mRNA level (squares in bottom row) after
combination therapy. The infected individual’s designation (e.g., 2003), the treatment regimen (AZT, zidovudine; 3TC, lamivudine; RIT, ritonavir; SQV, saquinavir;
IDV, indinavir), and the classiﬁcation of suppression are listed at the top of each panel. The lower limits of detection of plasma viral load and US mRNA were 50
copies/ml and 50 copies/mg of total RNA, respectively. NS, not suppressed.
6102 NOTES J. VIROL.strategies, such as activation, vaccination, or even cessation of
therapy (13), are designed to facilitate the decay of the latent
pool, then it is critical to have a simple, accurate test to identify
individuals with residual viral replication. Intensiﬁcation of
therapy may be prudent for individuals with any evidence of
residual replication. The detection of US mRNA in PBMC
may prove to be a useful marker in identifying these individuals
and may provide a virologic marker of response to intensiﬁed
therapies in individuals with undetectable plasma HIV-1 RNA.
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